Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its goal value decreased by analysis analysts at Wedbush from $31.00 to $30.00 in a be aware issued to traders on Thursday, Marketbeat Scores experiences. The agency at the moment has an “outperform” score on the inventory. Wedbush’s value goal factors to a possible upside of 69.38% from the inventory’s present value.
DNLI has been the subject of a number of different experiences. BTIG Analysis restated a “purchase” score and issued a $32.00 value goal on shares of Denali Therapeutics in a analysis report on Friday, December fifth. JPMorgan Chase & Co. raised their goal value on Denali Therapeutics from $24.00 to $26.00 and gave the inventory an “obese” score in a report on Tuesday, November 4th. Stifel Nicolaus set a $37.00 goal value on Denali Therapeutics in a analysis report on Monday, November seventeenth. Weiss Scores reiterated a “promote (d-)” score on shares of Denali Therapeutics in a analysis report on Wednesday, October eighth. Lastly, Cantor Fitzgerald reissued an “obese” score on shares of Denali Therapeutics in a analysis be aware on Monday, September eighth. Three equities analysis analysts have rated the inventory with a Robust Purchase score, 13 have assigned a Purchase score and one has given a Promote score to the corporate’s inventory. Based mostly on knowledge from MarketBeat.com, Denali Therapeutics at the moment has a consensus score of “Purchase” and a median goal value of $32.58.
Learn Our Newest Inventory Evaluation on Denali Therapeutics
Denali Therapeutics Worth Efficiency
Shares of DNLI inventory traded up $0.14 throughout noon buying and selling on Thursday, reaching $17.71. 321,262 shares of the corporate had been exchanged, in comparison with its common quantity of 1,556,583. The corporate has a market cap of $2.60 billion, a P/E ratio of -6.09 and a beta of 1.11. The corporate has a debt-to-equity ratio of 0.01, a fast ratio of 9.79 and a present ratio of 9.79. Denali Therapeutics has a 12 month low of $10.57 and a 12 month excessive of $24.34. The corporate’s 50 day shifting common value is $16.94 and its two-hundred day shifting common value is $15.24.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) final launched its earnings outcomes on Thursday, November sixth. The corporate reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. The corporate’s quarterly income was up .0% in comparison with the identical quarter final 12 months. Throughout the identical quarter within the earlier 12 months, the corporate posted ($0.63) earnings per share. On common, sell-side analysts count on that Denali Therapeutics will put up -2.71 earnings per share for the present 12 months.
Institutional Traders Weigh In On Denali Therapeutics
A number of institutional traders have not too long ago purchased and offered shares of the corporate. UBS AM A Distinct Enterprise Unit of UBS Asset Administration Americas LLC lifted its place in shares of Denali Therapeutics by 88.9% within the first quarter. UBS AM A Distinct Enterprise Unit of UBS Asset Administration Americas LLC now owns 6,766,916 shares of the corporate’s inventory valued at $91,996,000 after shopping for an extra 3,184,042 shares over the last quarter. SCS Capital Administration LLC acquired a brand new stake in Denali Therapeutics through the 1st quarter valued at $2,692,000. TT Worldwide Asset Administration LTD purchased a brand new place in Denali Therapeutics through the second quarter value $909,000. Schroder Funding Administration Group boosted its place in Denali Therapeutics by 32.5% through the second quarter. Schroder Funding Administration Group now owns 386,539 shares of the corporate’s inventory value $5,408,000 after buying an extra 94,744 shares through the interval. Lastly, Norges Financial institution purchased a brand new place in shares of Denali Therapeutics within the second quarter valued at about $55,224,000. Institutional traders personal 92.92% of the corporate’s inventory.
About Denali Therapeutics
(Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical firm, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative illnesses and lysosomal storage illnesses in america. The corporate’s transport automobile (TV)-enabled applications embody DNL310 ETV, an IDS enzyme substitute remedy program for MPS II; TAK-594/DNL593 which is in Section 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, in addition to different preclinical applications that concentrate on amyloid beta and HER2.
Featured Articles
Obtain Information & Scores for Denali Therapeutics Every day – Enter your electronic mail handle beneath to obtain a concise every day abstract of the newest information and analysts’ rankings for Denali Therapeutics and associated corporations with MarketBeat.com’s FREE every day electronic mail publication.
